Demystifying Schrems II for the cross-border transfer of clinical research data. Issue 2 (23rd October 2021)

• Record Type: Journal Article
• Authors: Liss, Joseph; Peloquin, David; Barnes, Mark; Bierer, Barbara E
• Is Part Of: Journal of law and the biosciences. Volume 8:Issue 2(2021)
• Publication Date: 2021-10-23
• Subjects: GDPR -- data privacy -- data protections -- clinical research -- FISA -- data transfer; Life sciences -- Law and legislation -- Periodicals; Science and law -- Periodicals; Law and biology -- Periodicals; Biotechnology -- Law and legislation -- Periodicals; Bioethics -- Periodicals; 344.0957
• DOI: 10.1093/jlb/lsab032
• Languages: English
• ISSNs: 2053-9711

Abstract

Abstract: The Courts of Justice of the European Union (CJEU) held in its July 2020 Schrems II decision that, in order for entities in other countries to import personal data from the European Economic Area (EEA), the importer must be able to provide data protections 'essentially equivalent' to those the EEA offers under its General Data Protection Regulation. The CJEU expressed particular concern that United States' national security intelligence gathering laws prevent U.S.-based entities from providing such protections. This decision has sharply limited the sharing of clinical research data from the EEA to the United States. After describing the pertinent aspects of the Schrems II decision, this article evaluates U.S. national security intelligence gathering frameworks, including Section 702 of the Foreign Intelligence Surveillance Act and Executive Order 12333. The article then leverages recent draft guidance from the European Data Protection Board to explain how entities may be able to adopt widely used contractual and technical measures, such as data pseudonymization, to provide 'essentially equivalent' protections in the clinical research context.